EGFR and neoplasm: A study conducted on erlotinib-resistant rodent models (having the human EGFR T790M erlotinib-resistance mutation) showed that several transcriptome changes occur that allow for metabolic adaptation, upregulation of oxidative stress defense mechanisms, and tumor progression pathways [56].